News

Replimune surges as Cantor upgrades on possible FDA U-turn on lead drug

Replimune (NASDAQ:REPL) stock surges as Cantor Fitzgerald upgrades, citing improved odds for approval of its lead drug after an FDA leadership change. Read more here.

Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs

Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics ...

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection Of Melanoma Drug - Hagens Berman

The lawsuit comes after Replimune investors witnessed a 77% collapse in the price of their shares on July 22 when the company announced that the Food and Drug Administration (FDA) had rejected its ...